Table of Contents
<< Previous Issue | Apr 2005 (Vol: 2005, Issue: 58) | Next Issue >> |
- Section: Business Commentaries
-
The Value of Valuations
- Section: Deal Trackers
-
Bioenvision
- Section: Distribution & Marketing
-
Mayne Pharma and PLIVA Enter Strategic Biogeneric Partnership for EPO and G-CSF
- Section: Features
-
Takeda and 3M Target HPV and Future Growth
-
Vertex Opts for Avalon to Progress VX-944
-
Product Sale and Purchase Agreements
-
Therapy Focus: Acne
- Section: General
-
Andrx Exits the Branded Drugs Business
-
De Novo Pharmaceuticals Ltd
- Section: Licensing
-
Sosei In-Licenses Otsuka’s Urology Drug
-
Osei Acquires Exclusive Rights to Bacterial Therapeutic from Miyarisan
- Section: Mergers & Acquisitions
-
Mylan and King Terminate Merger
-
Novartis Expands Generics Business
- Section: Research & Development
-
Biogen and Elan Lose Market Value as Tysabri® Withdrawn